Podcast: Download
Mark Samuels / LumaMed, LLC
Mark Samuels is co-founder and Chief Executive Officer of LumaMed, LLC. Mr. Samuels is an experienced public and private company executive and entrepreneur with an extensive background in technology and biomedical product development. Mr. Samuels has founded three companies and has raised over $65 million of investment, including an IPO. Mr. Samuels has led research, development, and commercialization efforts on four medical device products, including three currently on the market. Additionally, he has led research, development and commercialization efforts on a non-invasive replacement for cervical cancer screening currently undergoing Phase III pivotal trials at Guided Therapeutics, Inc. (ticker:GTHP)
Mr. Samuels earned his Master’s degree from Georgia Tech. He is a named inventor on nineteen (19) issued US patents and eight (8) US patent applications.
Shabbir Bambot / LumaMed, LLC
Shabbir Bambot is co-founder, Chairman and Chief Technology Officer of LumaMed, LLC. Dr. Bambot has a Ph.D. in Chemical Engineering and over 20 years of experience in developing innovative medical devices, business development, intellectual property development, regulatory strategy and clinical trials. He is currently co-founder and CTO at LumaMed, LLC, a company focused on developing imaging devices to help surgeons see cancer margins during surgery.
Dr. Bambot previously co-founded Guided Therapeutics, a company developing products for non-invasive and point of care cancer diagnosis. He has been instrumental in the successful launch of multiple medical diagnostic products, the AVL/Roche OPTI 2® blood chemistry analyzer and the SpectRx BiliChek® Non-invasive Bilirubin Analyzer and the Guided Therapeutics LuViva® Advanced Cervical Scan. He is a named inventor on 10 (ten) US patents and several additional applications under prosecution. He has several publications in the areas of clinical monitoring and diagnostics and is the recipient of several NIH SBIR grants totaling in excess of $6.5 million for developing non-invasive diagnostic devices. He frequently serves on review panels for scientific publications and NIH grant applications.
